Mirai Bio
PrivateLast Round
Series A
Sep 26, 2024
Total Funding Raised
$50M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Mirai Bio operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in September 2024.
Mirai Bio is a biotechnology company that provides an open, machine intelligence-driven platform for the end-to-end development, delivery, and manufacturing of genetic medicines.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mirai Bio Comparables
Compare Mirai Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mana.bio | 87% | |
| NanoVation Therapeutics | 85% | |
| Acuitas Therapeutics | 79% |
For institutional investors. Book with your work email.
Mirai Bio Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Mirai Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Flagship Pioneering | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 7, 2026
Open roles increased to 9, 2.1x the trailing average.
- Aug 31, 2026
Open roles increased to 7, 2.3x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- promotesAug 26, 2026
MiraiBio Group at Hitachi Solutions America, Ltd. promotes Jagesh V. Shah, Ph.D., to Chief Scientific Officer in Massachusetts on Aug 26th '26 as part of its leadership appointments.
- hiresAug 26, 2026
MiraiBio Group at Hitachi Solutions America, Ltd. appoints Jeff Luber as Board Chair on Aug 26th '26 in Massachusetts to guide strategic growth, financing, and partnership priorities.
- is_developingAug 26, 2026
MiraiBio Group at Hitachi Solutions America, Ltd. is developing a new model for nucleic acid medicine delivery that combines data-driven LNP design, in vivo learning, and integrated development capabilities to make delivery beyond the liver more precise, predictable, safe, and scalable in Massachusetts on Aug 26th '26.
- hiresAug 26, 2026
MiraiBio Group at Hitachi Solutions America, Ltd. names Kate Torchilin Chief Executive Officer and President and CEO-Partner at Flagship Pioneering in Massachusetts on Aug 26th '26, after she serves as interim CEO since Nov '25, to lead corporate strategy and business development.
- hiresAug 26, 2026
MiraiBio Group at Hitachi Solutions America, Ltd. hires Dr. Shah as Chief Scientific Officer on Aug 26th '26 to lead its scientific strategy and advance its delivery platform across new cells, tissues, and partner programs.
For institutional investors. Book with your work email.
Mirai Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mirai Bio's valuation, stock price, and market status.
Is Mirai Bio a public or private company?
Mirai Bio is a private company.
What is the current stock price of Mirai Bio?
Mirai Bio is a private company, so its shares have no public market price. Caplight tracks Mirai Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mirai Bio worth (valuation)?
Valuation information for Mirai Bio is not publicly available.
Can I buy Mirai Bio stock?
Mirai Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mirai Bio's last funding round?
Mirai Bio's most recent funding round was Series A on September 26, 2024.
Who are the main investors in Mirai Bio?
Key investors in Mirai Bio include Flagship Pioneering.
Will Mirai Bio IPO soon?
No public IPO plans have been announced for Mirai Bio.
How can I track Mirai Bio secondary market activity?
Caplight tracks bids, offers, and trades in Mirai Bio's shares on secondary markets.